Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.
Merus total Funding
Merus latest funding size
Time since last funding
|6 years ago|
|Sofinnova Ventures, Bay City Capital, Novartis Venture Fund, Pfizer Venture Investments, Life Sciences Partners, Rock Springs Capital, Pfizer, Tekla Capital Management, Johnson & Johnson Innovation, Novo A/S, RA Capital Healthcare, Aglaia Oncology Fund|
When was Merus founded?
Merus was founded in 2003.
Who are Merus key executives?
Merus's key executives are Bill Lundberg, Andrew Joe and Lex Bakker.
How many employees does Merus have?
Merus has 159 employees.
Who are Merus competitors?
Competitors of Merus include Kromaspects Scitec Solutions, Entera Bio and Catalyst Pharmaceuticals.
Where is Merus headquarters?
Merus headquarters is located at 62 Yalelaan, Utrecht.
Where are Merus offices?
Merus has offices in Utrecht and Cambridge.
How many offices does Merus have?
Merus has 3 offices.
Receive alerts for 300+ data fields across thousands of companies